HB5629 would void the Department of Health and Human Services final rule titled “Medications for the Treatment of Opioid Use Disorder,” effectively removing federal guidance on MOUD across most providers. The bill contains a single Section 1 with two subsections: (a) declares the final rule shall have no force or effect; (b) preserves the portion of the rule that makes modifications to Subpart B of Part 8 of Title 42 of the CFR relating to accreditation of opioid treatment programs.
In short, federal MOUD policy would be eliminated, but the accreditation framework tied to OTPs would remain in force. The bill shifts regulatory influence away from federal MOUD standards and toward state-level policy and existing accreditation mechanisms, creating a clearer divergence between MOUD practice standards and OTP accreditation rules.
At a Glance
What It Does
The final rule on medications for the treatment of opioid use disorder is declared to have no force or effect, with an explicit exception for the OTP accreditation changes.
Who It Affects
Federal health agencies implementing MOUD policy, providers delivering MOUD, opioid treatment programs, and accreditation bodies.
Why It Matters
It removes federal MOUD policy guidance while preserving accreditation-based oversight, shifting regulatory leverage to states and accrediting entities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 1 of HB5629 targets a specific federal regulatory action: the HHS final rule titled Medications for the Treatment of Opioid Use Disorder, published in February 2024. The bill states that, except for a defined exception, the final rule shall have no force or effect.
The exception preserves the portion of the rule that makes modifications to Subpart B of Part 8 of Title 42 CFR, which governs the accreditation of opioid treatment programs (OTPs).
Practically, this means federal direction on how medications for opioid use disorder should be implemented in most settings would be removed, while the changes to OTP accreditation requirements would remain. The net effect is a removal of centralized MOUD practice standards at the federal level and a retention of accreditation standards at the federal level that apply to OTPs.
The policy landscape would then rely more on state-level approaches to MOUD and the ongoing accreditation framework for OTPs, rather than a single federal rule guiding MOUD implementation across providers.The bill does not create new MOUD programs or funding mechanisms. Instead, it repositions regulatory authority from a federal MOUD rule to the state regulatory environment and the existing accreditation regime.
How access to MOUD and the quality of its delivery will be affected will depend on state policies and how OTP accreditation requirements interact with state standards.
The Five Things You Need to Know
The bill voids the HHS final rule on medications for the treatment of opioid use disorder.
An explicit exception preserves the rule’s modifications to OTP accreditation under Subpart B of Part 8, Title 42 CFR.
The final rule cited in HB5629 is 89 Fed. Reg. 7549 (Feb 2, 2024).
The mechanism uses the term "shall have no force or effect" for the broad MOUD rule while carving out an OTP accreditation exception.
The net effect is a shift from federal MOUD policy to state-level MOUD policy and existing OTP accreditation frameworks.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Rule Relating to Medications for OUD
Section 1(a) states that, except as provided by subsection (b), the final rule titled Medications for the Treatment of Opioid Use Disorder shall have no force or effect. This language effectively nullifies the federal MOUD rule across applicable federal rulemaking and administrative actions, removing centralized federal standards for MOUD implementation.
Exception for OTP Accreditation
Section 1(b) provides an explicit exception to the general voiding of the MOUD rule. The exception retains the portion of the final rule that makes modifications to Subpart B of Part 8 of Title 42 CFR, relating to the accreditation of opioid treatment programs. This preserves the federal accreditation framework even as other MOUD provisions lose force.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State health departments gain flexibility to set MOUD policy without being bound by a federal MOUD rule.
- Health insurers and employer-sponsored plans benefit from reduced federal MOUD mandates.
- OTP accreditation bodies maintain visibility and influence through the preserved accreditation provisions.
Who Bears the Cost
- Patients with opioid use disorder may face less federal guidance on MOUD access and coverage.
- MOUD service providers may encounter regulatory uncertainty as federal MOUD standards are voided.
- States and local jurisdictions may need to fill policy gaps left by the absence of a federal MOUD rule, potentially increasing administrative burden.
Key Issues
The Core Tension
The core tension is between ensuring uniform federal MOUD practice standards and enabling state-level policy autonomy, while still maintaining a credible, federal-anchored accreditation framework for OTPS.
The central tension in HB5629 is the trade-off between removing federal MOUD policy to allow state-level experimentation and preserving an accreditation framework that theoretically provides ongoing oversight for OTPs. This split raises questions about consistency of care for patients with OUD, especially across state lines, and about the adequacy of state resources to regulate MOUD in the absence of a national rule.
It also places heavier importance on the governance of OTP accreditation and on how accreditation bodies interpret and enforce the remaining standards. Regulatory clarity could suffer in the transition, while the preservation of OTP accreditation may provide a continuing, though narrower, federal touchpoint for program quality.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.